Insmed Incorporated
NASDAQ:INSM · NASDAQ Global Select
-$2.73 today
Vol 16.08M · Avg 3.31M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:INSM · Revenue to Net Income
Key Ratios
Analysis
$819.6M of revenue converted into -$1.2B of net income for the selected period. Gross margin is 80.1% and net margin is -184.3%, showing how much revenue survives after costs and taxes. EPS is $-5.75, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $606.4M +66.7% | $363.7M +19.2% | $305.2M +24.4% | $245.4M +30.2% | $188.5M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $124.9M +45.6% | $85.7M +30.8% | $65.6M +19.0% | $55.1M +24.9% | $44.2M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $481.5M +73.2% | $278.0M +16.0% | $239.6M +26.0% | $190.2M +31.8% | $144.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 79.4% +3.0pp | 76.4% -2.1pp | 78.5% +1.0pp | 77.5% +1.0pp | 76.6% | 9.8% | 28.9% | 38.3% |
| Research & Development | $771.1M +28.9% | $598.4M +4.8% | $571.0M +43.6% | $397.5M +45.7% | $272.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $701.2M +52.1% | $461.1M +33.9% | $344.5M +29.6% | $265.8M +13.5% | $234.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $1.7B +43.4% | $1.2B +21.8% | $949.3M +46.6% | $647.6M +24.7% | $519.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $16.4M +49.4% | $11.0M +4.1% | $10.6M +2.4% | $10.3M -27.2% | $14.2M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$1.2B -43.1% | -$818.8M -24.0% | -$660.2M -47.6% | -$447.4M -16.6% | -$383.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -193.2% +31.9pp | -225.1% -8.8pp | -216.3% -34.0pp | -182.3% +21.2pp | -203.6% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$1.2B -34.0% | -$878.3M -23.8% | -$709.6M -55.2% | -$457.3M -21.9% | -$375.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -194.0% +47.4pp | -241.5% -9.0pp | -232.5% -46.1pp | -186.4% +12.6pp | -199.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $60.7M +13.8% | $53.3M +26.5% | $42.1M +280.2% | $11.1M +6268.4% | $174.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $83.8M -1.3% | $84.9M +3.9% | $81.7M +208.9% | $26.4M -34.7% | $40.5M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$95.0M -198.7% | -$31.8M +14.9% | -$37.4M -63.8% | -$22.8M +62.8% | -$61.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$1.3B -39.7% | -$910.1M -21.8% | -$747.0M -55.6% | -$480.2M -10.0% | -$436.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -209.7% +40.5pp | -250.2% -5.5pp | -244.8% -49.1pp | -195.7% +35.9pp | -231.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $5.0M +35.6% | $3.7M +45.1% | $2.6M +84.7% | $1.4M +178.7% | -$1.8M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$1.3B -39.7% | -$913.8M -21.9% | -$749.6M -55.7% | -$481.5M -10.8% | -$434.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | -210.5% +40.7pp | -251.2% -5.6pp | -245.6% -49.3pp | -196.3% +34.4pp | -230.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$6 -15.1% | -$6 -4.3% | -$5 -36.6% | -$4 -0.8% | -$4 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$6 -15.1% | -$6 -4.3% | -$5 -36.6% | -$4 -0.8% | -$4 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $213.6M +30.2% | $164.0M +16.8% | $140.4M +14.1% | $123.0M +9.7% | $112.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $213.6M +30.2% | $164.0M +16.8% | $140.4M +14.1% | $123.0M +9.7% | $112.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Cardinal Health, Inc.
NYSE:CAH
$52.00B
Takeda Pharmaceutical Company Limited
NYSE:TAK
$49.39B
Humana Inc.
NYSE:HUM
$43.33B
Haleon plc
NYSE:HLN
$39.60B
Agilent Technologies, Inc.
NYSE:A
$35.95B
Alcon Inc.
NYSE:ALC
$31.56B
BeOne Medicines Ltd.
NASDAQ:ONC
$28.91B
GE HealthCare Technologies Inc.
NASDAQ:GEHC
$28.07B
IQVIA Holdings Inc.
NYSE:IQV
$28.02B
ResMed Inc.
NYSE:RMD
$27.35B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does INSM generate?
Insmed Incorporated (INSM) reported $606.42M of revenue in fiscal 2025.
Is INSM profitable?
Insmed Incorporated (INSM) reported -$1,276,775,000.00 of net income, with a net margin of -210.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.